ENVB — Enveric Biosciences, Inc.
$1.51
$-0.00 (-0.26%)
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.
Market Cap
$6.78M
Forward P/E
-1.1x
52-Week Range
N/A
ENVB Price History
Revenue vs. Net Income
$0
Revenue · FY2024
Annual. Net margin is shown under each year.
Free Cash Flow
-$7.7M
FCF · FY2024
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-604.7%
ROCE · FY2024
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.1x
Assets ÷ liabilities · FY2024
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+249.4%
Dilution · FY2024
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
